Skip to main content
OpenTrials
Completed

NCT Number: NCT03350425

Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients

The investigators compare two strata of vaccinated patients: those recently vaccinated and those vaccinated more than two years ago. The primary objective is to compare pneumonia rates between the groups. As exploratory objectives, the investigators will describe the anti-pneumococcal antibody titers in hemodialysis patients as a function of time since vaccination, and determine factors influencing antibody kinetics. Further exploratory objectives investigate the relationship between antibody titers and the incidence of pneumonia in hemodialysis patients and extrapolate a possible cut-off for protection from pneumonia.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Participating sites will screen all hemodialysis patients at their outpatient dialysis clinic for eligibility. Eligible patients will be approached and informed by their treating physician. If a patient agrees to participate in the study and to sign an informed consent form, basic data regarding vaccination history, underlying disease, etc. will be entered or electronically imported into the study eCRF. Pneumococcal antibody titers will be drawn at baseline and every 3 months. For newly vaccinated patients baseline titers will be drawn 4 weeks after the vaccination. DZIF CTUs will coordinate titer assessment schedules and inform the participating physicians of upcoming blood samplings. The samples will be taken on dialysis days and thus constitute only a minimal additional burden for both patients and physicians. DZIF CTUs will actively follow up on study patients for 2 years after enrolment. This follow-up will include validation of all hospitalizations and deaths documented in an electronic registry database to assess whether the primary endpoint (pneumonia) occurred. Additionally, dialysis units will be contacted every 6 months to assess if pneumonia occurred, which did not require hospitalization. DZIF CTUs will document titer assessment results in the eCRF. Titers will not be disclosed to the attending physicians because revaccination due to knowledge of titers would produce bias. All therapies and diagnostics including vaccinations will be administered solely as part of clinical routine and as recommended by appropriate guidelines (e.g. RKI STIKO recommendations).

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent form including enrolment in registry database (QiN-registry)
  • Patients with stage 5 chronic kidney disease treated with chronic hemodialysis
  • Patients who are either already vaccinated or eligible and willing to be vaccinated against pneumococcal infection in accordance with current STIKO recommendations
  • Age of 18 years or older

Exclusion criteria

  • Patients unwilling/ineligible for vaccination under current STIKO recommendations

Treatment and study plan

Primary outcomes

  1. Comparison of pneumonia rates between newly vaccinated hemodialysis patients and those vaccinated against pneumococcal infection more than 2 years ago

    Time frame: 2 years

Secondary outcomes

  1. Pneumococcal antibody kinetics as a function of time since vaccination.

    Time frame: 2 years

    Description of antibody titers in hemodialysis patients as a function of time since vaccination.

  2. Factors influencing antibody kinetics

    Time frame: 2 years

    Determination of factors influencing antibody kinetics (e.g. age, prior or ongoing immunosuppression, medication, prior vaccination history) by multiple multivariate models

Other outcomes

  1. Exploration of the relationship between anti-pneumococcal antibody titers and a possible cut-off for protection from pneumonia

    Time frame: 2 years

    Exploration of the relationship between anti-pneumococcal antibody titers and the incidence of pneumonia in hemodialysis patients and extrapolation of a possible cut-off for protection from pneumonia.

  2. Factors influencing pneumonia and vaccine response

    Time frame: 2 years

    Evaluation of role of patient history (e.g. underlying kidney disease) and clinical course (e.g. prior hospitalizations) on pneumonia and vaccine response.

Sponsors and collaborators

Lead sponsor

University of Cologne

Other

Collaborators

  • German Center for Infection Research

Registry information

Acronym: DOPPIO

Important dates

Study start
2017
Primary completion
2022
Study completion
2022
First posted
Nov 22, 2017
Registry last updated
Dec 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.